Publicación del resumen AVA6000 por AACR
8 de abril de 2024
Grupo Avacta plc
("Avacta" o "el Grupo" o "la Compañía")
AVA6000 Abstract Release by AACR and Full Presentation Update
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that the abstract of the poster to be presented at the American Association of Cancer Research ("AACR") Annual Meeting in San Diego, California on Tuesday 9 April has now been released by AACR.
The poster presentation will be based on data from the Phase 1a trial of AVA6000, a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by fibroblast activation protein (FAP) in the tumor microenvironment.
Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.
Detalles de la presentación
Posición: A Phase 1 trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors
Título de la sesión: First-in-Human Phase 1 Clinical Trials 2
Fecha y hora de la sesión: Tuesday 9 April 2024 9:00 AM - 12:30 PM (PDT)
Ubicación: San Diego Convention Center, San Diego CA USA
Abstract Presentation Number: CT188
Primer autor: Udai Banerji, MD, PhD, The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust
The presentation will include updated data from the Phase 1 trial beyond those included in the abstract. A copy of the abstract will be available on Avacta's website at: https://avacta.com/about/scientific-resources/.
Copies of the poster will be available on Avacta's website following the conference at: https://avacta.com/about/resources/posters/.
Christina Coughlin will provide a video presentation overview examining the data presented in the poster. This will be available on 10th April at https://avacta.com/investors/documents-presentations/.
Alastair Smith, Avacta Chief Executive Officer, will also be hosting a webinar on Wednesday, April 10 2024 at 5.30pm BST to discuss the data. Registration for the event is via the following link:
https://www.turnerpope.com/register/
-Termina
Para obtener más información de Avacta Group plc, comuníquese con:
Grupo Avacta plc Alastair Smith, director ejecutivo Tony Gardiner, director financiero Michael Vinegrad, director de comunicaciones del grupo
| Tel: + 44 (0) 1904 21 7070 www.avacta.com |
| |
Stifel Nicolaus Europa limitada (Nómada y conjunta Broker) Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Ben Good
| Tel: + 44 (0) 207 710 7600 www.stifel.es |
Peel Hunt (Conjunto Broker) James Steel / Chris Golden / Patrick Birkholm | Tel: + 44 (0) 207 418 8900 www.peelhunt.com
|
Consilium ICR (Medios e IR) Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji |
|
Acerca de AVA6000
AVA6000, Avacta Therapeutics' lead oncology program, is a peptide drug conjugate consisting of doxorubicin conjugated with a peptide moiety that is specifically cleaved by fibroblast activation protein (FAP) in the tumor microenvironment (TME). FAP is selectively overexpressed in many solid tumors. The peptide moiety (pre|CISIONTM) prevents cellular entry of doxorubicin unless cleaved by FAP, thus enabling targeted delivery of doxorubicin directly to the TME.
Acerca de Avacta Group plc - https://www.avacta.com
Avacta Group es una empresa con sede en el Reino Unido centrada en mejorar los resultados de la atención sanitaria mediante tratamientos y diagnósticos específicos del cáncer.
Avacta has two divisions: an oncology biotech division harnessing proprietary therapeutic platforms to develop novel, highly targeted cancer drugs, and a diagnostics division, which is executing on an M&A led growth strategy to create a full-spectrum diagnostics business focused on supporting healthcare professionals and broadening access to testing. Avacta's two proprietary platforms, Affimer® and pre|CISION™ underpin its cancer therapeutics whilst the diagnostics division leverages the Affimer® platform to drive competitive advantage in its markets.
The pre|CISION™ platform modifies chemotherapy to be activated only in the tumour tissue, reducing systemic exposure and toxicity. This is achieved by harnessing an enzyme called FAP which is highly upregulated in most solid tumours compared with healthy tissues, turning chemotherapy into a "precision medicine". The lead pre|CISION™ programme, AVA6000 a tumour activated form of doxorubicin, is in Phase 1 studies and has shown dramatic improvement in safety compared with standard doxorubicin, and early signs of clinical activity.
Para registrarse para recibir alertas de noticias por correo electrónico, vaya a https://avacta.com/investors/investor-news-email-alerts/
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.